Forte Biosciences, Inc.
FB102
celiac disease
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews FB102 for celiac disease around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“FB102 Received Fast Track Designation in Celiac Disease”